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Abstract
Background: Chronic hyperglycemia confers increased risk for long-term diabetes-associated complications and
repeated hemoglobin A1c (HbA1c) measures are a widely used marker for glycemic control in diabetes treatment
and follow-up. A recent genome-wide association study revealed four genetic loci, which were associated with
HbA1c levels in adults with type 1 diabetes. We aimed to evaluate the effect of these loci on glycemic control in
type 2 diabetes.
Methods: We genotyped 1,486 subjects with type 2 diabetes from a Norwegian population-based cohort (HUNT2)
for single-nucleotide polymorphisms (SNPs) located near the BNC2, SORCS1, GSC and WDR72 loci. Through
regression models, we examined their effects on HbA1c and non-fasting glucose levels individually and in a
combined genetic score model.
Results: No significant associations with HbA1c or glucose levels were found for the SORCS1, BNC2, GSC or WDR72
variants (all P-values > 0.05). Although the observed effects were non-significant and of much smaller magnitude
than previously reported in type 1 diabetes, the SORCS1 risk variant showed a direction consistent with increased
HbA1c and glucose levels, with an observed effect of 0.11% (P = 0.13) and 0.13 mmol/l (P = 0.43) increase per risk
allele for HbA1c and glucose, respectively. In contrast, the WDR72 risk variant showed a borderline association with
reduced HbA1c levels (b = -0.21, P = 0.06), and direction consistent with decreased glucose levels (b = -0.29, P =
0.29). The allele count model gave no evidence for a relationship between increasing number of risk alleles and
increasing HbA1c levels (b = 0.04, P = 0.38).
Conclusions: The four recently reported SNPs affecting glycemic control in type 1 diabetes had no apparent effect
on HbA1c in type 2 diabetes individually or by using a combined genetic score model. However, for the SORCS1
SNP, our findings do not rule out a possible relationship with HbA1c levels. Hence, further studies in other
populations are needed to elucidate whether these novel sequence variants, especially rs1358030 near the SORCS1
locus, affect glycemic control in type 2 diabetes.
Background
Good glycemic control may slow or prevent long-term
diabetes-associated complications, preserve b-cell func-
tion, and improve long-term outcomes in both type 1
and type 2 diabetes [1,2]. Chronic hyperglycemia is also
a risk factor for cardiovascular disease and all-cause
mortality in persons without diabetes [3,4]. Individuals
with diabetes often have difficulties attaining the recom-
mended HbA1c goals, and inter- and intra-individual
variability in HbA1c is commonly observed, even for
patients using the same treatment regimen. Medical
conditions that influence erythrocyte turnover, as well
as genetic hereditary anemia and iron storage disorders,
affect the HbA1c level. Moreover, several twin and
family studies have demonstrated a heritable component
in both HbA1c and fasting blood glucose levels, but
these measures are not genetically correlated to each
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also common genetic variants may affect HbA1c and
fasting glucose in both diabetic and non-diabetic indivi-
duals via both glycemic and non-glycemic pathways
[5,8-19], little is known about the genetic background of
HbA1c in type 2 diabetes.
Recently, Paterson and colleagues conducted a gen-
ome-wide association study (GWAS) on longitudinal
repeated measures of HbA1c in 1,441 patients with type
1 diabetes collected from the Diabetes Control and
Complications Trial (DCCT). They reported evidence of
one major locus for glycemic control near SORCS1,a s
measured by both HbA1c and glucose, and three other
loci (near BNC2, GSC and WDR72) achieving associa-
tion close to genome-wide significance [20]. The clinical
and biological significance of these findings remains to
be demonstrated. They may, however, point to new
pathways relevant for glycemic physiology [21]. We
aimed to evaluate the individual and cumulative effect
of the four novel loci on glycemic control in unselected
individuals with type 2 diabetes collected from a Norwe-
gian population-based study (HUNT2).
Methods
HUNT2 subjects and ethics
The study population has recently been described [22-24].
In short, the participants were ≥20 years of age (range 21-
97) and comprised the total diabetes population drawn
from an extensive population-based study (the HUNT2
Study). Diagnosis of diabetes was self-reported or identi-
fied by standard tests if random glucose was >8.0 mmol/l.
G e n o m i cD N Aw a sa v a i l a b l ef o r1 , 8 5 0( 9 4 % )d i a b e t i c
participants. Eight subjects with genetically verified matur-
ity-onset diabetes of the young [24] and 205 subjects eval-
uated as having type 1 diabetes were excluded. More
detailed inclusion and exclusion criteria for the diabetic
participants have been described previously [22]. Of the
1,637 type 2 diabetic participants enrolled in the study, 73
subjects had missing data on HbA1c and another 44 sub-
jects had missing BMI data. For those subjects with data,
the range was 4.1-16.7% and 16.9-49.5 kg/m
2 for HbA1c
and BMI, respectively. In addition, 34 individuals were
excluded due to low genotyping quality or missing DNA.
The study group finally consisted of 1,486 individuals with
t y p e2d i a b e t e s .T h es t u d yw a sa p p r o v e db yt h eR e g i o n a l
Committee for Research Ethics and the Norwegian Data
Inspectorate, and was performed according to the latest
version of the Helsinki Declaration. All participants gave
written informed consent.
SNP selection, genotyping and quality control
We included only the four SNPs from Paterson et al.
[20] which had shown the strongest association with
glycemic control in type 1 diabetes. These are the non-
coding SNPs rs10810632, rs1358030, rs11624318 and
rs566369 located in or close to the BNC2, SORCS1, GSC
and WDR72 genes, respectively. The genotyping was
carried out by the multiplex MassARRAY
® iPLEX™
System (SEQUENOM Inc., San Diego, CA, USA) at the
technology platform CIGENE, Ås, Norway. The final
genotyping success rate was >95% for each SNP, with an
average of 98.5%. For the internal controls, the genotyp-
ing concordance rate was 100% (n = 80 concordant
calls). All SNPs examined were consistent with Hardy-
Weinberg equilibrium (P > 0.05).
Statistical analysis
We assessed the effect of each risk variant on single
cross-sectional HbA1c levels and on non-fasting glucose
levels using linear regression models assuming additive
effects of allele dosage. Subsequently, we studied the
combined SNP effect by using an allele counting
method to assign a genetic risk score to each subject
according to the total number of risk alleles that they
carried. The allele counting method assumed equal and
additive effects for each of the different variants. All
analyses were conducted using age, sex and BMI as cov-
ariates, and none of the phenotypes analyzed were loga-
rithmically transformed since a transformation did not
influence the distributions and results noticeably.
Detailed information regarding medical treatment was
not available. Since our results represents a basic repli-
cation of previously reported findings, P-values pre-
sented in this study are two-sided, but was not
corrected for the number of test performed. All analyses
were carried out using the PLINK software [25] and
Stata SE v10.0 for Windows (Stata Corp LP, Brownsville,
TX, USA). We had >80% power to detect a total QTL
variance of ≥0.5% at the 0.05-level, assuming additive
effects, allele frequency of 0.1 or more [26].
Results
Table 1 shows the clinical characteristics for the 1,486
individuals analyzed in the present study. Age, sex and
Table 1 Clinical characteristics of the 1,486 type 2
diabetic participants included in the study
Individuals (n) 1,486
Sex (male/female) 706/780
Age (years at examination) 68.1 ± 11.9
BMI (kg/m
2) 29.2 ± 4.8
HbA1c (%) 8.1 ± 1.8
Non-fasting serum glucose (mmol/l) 9.6 ± 4.2
Serum triglyceride (mmol/l) 2.5 ± 1.6
Serum cholesterol (mmol/l) 6.2 ± 1.3
Serum HDL cholesterol (mmol/l) 1.2 ± 0.4
Values are presented as means ± SD.
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ates. The risk alleles were defined according to Paterson
et al. [20] and we assumed an additive model for all
four SNPs throughout this study, based on the results
reported in the DCCT study [20]. The results did not
change notably in view of dominant or recessive genetic
models (not shown). We observed allele frequencies
similar to the frequencies reported in individuals with
type 1 diabetes [20]. The mean HbA1c by genotype for
each of the SNPs are presented in Table 2.
In the individual SNP analysis, none of the risk alleles
reached statistical significance with either increased
HbA1c measures or increased non-fasting serum glucose
levels (all P-values > 0.05, Table 3). Although the observed
effects were non-significant and of much smaller magni-
tude than previously reported in type 1 diabetes, the
SORCS1 risk variant showed a direction consistent with
increased HbA1c and glucose levels, with an observed
effect of 0.11% (P = 0.13) and 0.13 mmol/l (P =0 . 4 3 )
increase per risk allele for HbA1c and glucose, respectively
(Table 3). In contrast, the WDR72 risk variant showed a
borderline association with reduced HbA1c levels (b =
-0.21, P = 0.06, Table 3), and direction consistent with
decreased glucose levels (b =- 0 . 2 9 ,P = 0.29, Table 3).
Even though the four examined loci were not signifi-
cantly associated with increased HbA1c values at an
individual level, three of the four risk variants showed
concordance in allelic direction in which individuals car-
rying the risk allele had higher HbA1c. When we
included all four variants in a combined genetic score
model we observed, however, no evidence for a relation-
ship between increasing number of risk alleles and
increasing HbA1c levels (P = 0.38). Each additional risk
allele demonstrated an increase in HbA1c of approxi-
mately 0.04% (Table 3, Figure 1).
Discussion
To our knowledge, this study is the first attempt to eval-
uate the effect of the SNPs found by Paterson [20] with
regard to glycemic control in type 2 diabetes. None of
the SNPs were found associated with glycemic control
in type 2 diabetes, either individually or combined by
applying an allele count score. Hence, we were not able
to confirm the strong associations recently reported in
the DCCT genome-wide association study for HbA1c in
the context of treated type 1 diabetes [20].
Using the same definition of the risk alleles as the
DCCT study, the WDR72 SNP showed a borderline asso-
ciation with reduced and not increased HbA1c levels in
our study. Thus, our results do not support a role of the
WDR72 SNP on glycemic control as found in the DCCT
study. The different pathophysiology between type 1 and
type 2 diabetes could be one of the explanations why our
results do not lend support to the finding that the four
SNPs reported in the DCCT genome-wide association
s t u d y[ 2 0 ]a r eg e n e t i cs u s c e p t ibility factors for glycemic
control in type 2 diabetes. In addition to a strong associa-
tion with HbA1c, the BNC2 and SORCS1 risk alleles have
revealed associations with mean glucose levels in type 1
diabetes [20], suggesting that these genetic variations
affect HbA1c through their effects on glucose. We
obtained no support for any associations between the
BNC2 and SORCS1 SNPs and non-fasting serum glucose.
The SORCS1 risk allele indicated, however, an effect con-
sistent in direction with its effect on HbA1c.
There are some prior data supporting a role of the
SORCS1 gene in glycemic traits. SORCS1 encodes a
sortilin-related vacuolar protein sorting 10 domain-con-
taining receptor, which binds to platelet-derived growth
factor. A quantitative trait locus for fasting insulin in
t h es y n t e n i cr e g i o ni nm i c eh a sb e e nd e s c r i b e d[ 2 7 ] ,
with further independent evidence obtained in rats for
post-intra-peritoneal glucose tolerance [28]. Two studies
have also demonstrated modest evidence for association
between SNPs in SORCS1 and fasting insulin, insulin
sensitivity and insulin resistance in humans [29,30].
However, no association has been found with type 2 dia-
betes. Considering our results in light of the previous
reported results and features for SORCS1,w ec a nn o t
refute a possible link between SORCS1 and glycemic
control in type 2 diabetes.
The BNC2, WDR72 and GSC genes encode a zinc finger
protein, a putative b propeller expected to be involved in
protein-protein interactions and a transcription factor of
Table 2 Genotype-specific means for single cross-sectional HbA1c levels in 1,486 subjects with type 2 diabetes
Nearest gene SNP Common homozygote Heterozygote Rare homozygote Minor allele* Major allele* MAF MISS #
N Mean SD N Mean SD N Mean SD
BNC2 rs10810632 1215 8.05 0.52 257 8.12 0.11 13 7.95 0.65 C T 0.09 1
SORCS1 rs1358030 648 7.94 0.07 622 8.16 0.07 139 8.02 0.16 C T 0.32 77
GSC rs11624318 908 8.07 0.06 500 8.02 0.08 76 8.11 0.21 A C 0.22 2
WDR72 rs566369 1218 8.02 0.05 251 8.18 0.12 10 8.89 0.74 A G 0.09 7
Risk alleles are defined according to Paterson et al. [20], and underlined and highlighted in bold.
MAF = minor allele frequency.
MISS# = number of individuals with missing genotype data.
*Alleles are indexed from the forward strand of the human reference sequence NCBI Build 36.
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Their exact function is unknown. Except for the results
reported by Paterson and colleagues [20] none of these
gene regions have previously been shown to be associated
with glycemic traits in humans or animals. We found no
evidence of association for any of these loci with glycemia
in our type 2 diabetes cohort. The possibility nevertheless
exists that the analysed SNP or genetic variants in strong
linkage disequilibrium with these SNPs, are involved in
glycemia, but that they have weak effects and/or are popu-
lation specific. Our results therefore emphasize the need
for further replication studies if one is to be successful in
defining the true genetic risk factors involved in glycemic-
related traits.
There are limitations of our study. We had access to
only one HbA1c and non-fasting blood glucose value
for each case, in contrast to the repeated measurements
used by the DCCT investigators during the course of a
carefully controlled clinical trial. Furthermore, the use of
HbA1c as a quantitative trait modulated by genetic fac-
tors must be taken with caution in the context of phar-
macological treatment, since treatment as an
environmental variable may overwhelm the genetic sig-
nal. Whereas the DCCT investigators attempted to con-
trol for this, we had no access to information on
medical treatment in the current study. Thus, our data
may be confounded by environmental factors and can-
not be considered a straight-forward replication study.
Our study has, however, also several important
strengths. The HUNT cohort is a well-characterized,
stable (net emigration around 0.3% per year) and ethni-
c a l l yu n i f o r m( l e s st h a n3 %o ft h ep e o p l ea r eo fn o n -
Caucasian origin) population from a clearly defined
region of Norway [31]. Our study participants were part
of an all-population-inclusive survey with high atten-
dance. Hence, possible selection biases that can arise
when studying referral patients or patients selected for
inclusion in clinical intervention studies were avoided.
The HUNT samples have previously been validated by
genotyping of known type 2 diabetes risk variants
[23,32] indicating that the HUNT population contains a
representative diabetes cohort. Furthermore, we
observed allele frequencies similar to the frequencies
reported by Paterson et al [20], arguing against pro-
blems with population stratification. Finally, our study
was conducted in one data set avoiding loss of power
and, although the design was different than that of the
initial report [20], we tested identical SNPs.
Conclusions
The four recently reported loci affecting glycemic con-
trol in type 1 diabetes patients had no apparent effect
on HbA1C levels in type 2 diabetes, neither individually
nor by using a combined genetic score model. For the
SORCS1 SNP however, we cannot refute a possible rela-
tionship with HbA1c. Hence, further studies in other
Table 3 Effects observed for the individual risk alleles and for the combined genetic scores on HbA1c and non-fasting
serum glucose levels in 1,486 individuals with type 2 diabetes
Individual SNP effects HbA1c Non-fasting serum glucose
Gene region SNP RAF Effect size Std Error P-value Sample size Effect size Std Error P-value Sample size
BNC2 rs10810632 0.09 (C) 0.07 0.11 0.57 1485 -0.00 0.26 0.99 1484
SORCS1 rs1358030 0.32 (C) 0.11 0.07 0.13 1409 0.13 0.17 0.43 1408
GSC rs11624318 0.78 (C) 0.03 0.08 0.75 1484 -0.14 0.18 0.45 1483
WDR72 rs566369 0.91 (G) -0.21 0.12 0.06 1479 -0.29 0.27 0.29 1478
Combined SNP effect based upon an allele
count score
0.04 0.04 0.38 1403 -0.05 0.1 0.66 1402
All effect sizes represent the change in HbA1c or non-fasting serum glucose per risk allele. Age, sex and BMI were included as covariates in the regression
models. P values are two-sided and are unadjusted for multiple testing.
RAF: risk allele frequency.
Figure 1 Mean HbA1c (black circles) and frequency (bars) of
type 2 diabetes individuals plotted against the number of risk
alleles carried, and the relationship between BNC2
(rs10810632), SORCS1 (rs1358030), GSC (rs11624318) and
WDR72 (rs566369) combined genotypes and mean HbA1c. Only
individuals genotyped for all variants are included (n = 1,403). The
black line is the fitted HbA1c linear regression line with the area
between the dashed curves representing the 95% confidence
interval.
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sequence variants, especially rs1358030 near the
SORCS1 locus, affect glycemic control in type 2 diabetes.
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